Compare OPRX & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | RNA |
|---|---|---|
| Founded | 2006 | 2025 |
| Country | United States | United States |
| Employees | 105 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.1M | 141.3M |
| IPO Year | 2008 | 2025 |
| Metric | OPRX | RNA |
|---|---|---|
| Price | $7.68 | $7.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $12.30 | ★ $22.00 |
| AVG Volume (30 Days) | 181.3K | ★ 203.2K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,429,000.00 | N/A |
| Revenue This Year | N/A | $88.07 |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $4.54 | $7.49 |
| 52 Week High | $15.59 | $73.06 |
| Indicator | OPRX | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 37.22 | 34.12 |
| Support Level | $7.23 | $7.56 |
| Resistance Level | $8.30 | $8.50 |
| Average True Range (ATR) | 0.69 | 0.36 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 38.21 | 6.58 |
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.